Current label evidence
Wegovy and Ozempic report different grouped local-reaction data
The current manufacturer Wegovy label, published June 30, 2026, reports injection-site reactions in 1.4% of treated adults and 1% of placebo-treated adults in weight-reduction trials. The grouped category included itching, redness, inflammation, firmness, and irritation. The current Ozempic injection label, published June 10, 2026, reports grouped injection-site reactions such as discomfort or redness in 0.2% of treated patients in placebo-controlled trials. The products, indications, populations, presentations, and study definitions differ, so their percentages are context—not a head-to-head comparison or a personal-risk forecast.
- Do not present 1.4%, 1%, or 0.2% as a rate for pain, swelling, burning, a lump, delayed redness, infection, allergy, or any other single finding.
- Neither label establishes one normal reaction diameter, onset, severity, cause, or duration.
- A grouped trial rate cannot diagnose one skin finding or show whether a medicine, device, supply, skin exposure, infection, allergy, or another cause contributed.
Symptom pattern
“Injection-site reaction” describes a location, not one diagnosis
A local reaction may be described as redness, itching, irritation, discomfort, tenderness, warmth, firmness, swelling, bruising, a rash, or another change near the injection area. Those findings can overlap with simple irritation, contact dermatitis, bleeding, infection, hypersensitivity, or tissue injury. The most useful review focuses on timing and trend: when the finding appeared, whether it is stable or expanding, whether pain or warmth is increasing, whether it returns after multiple injections, and whether symptoms occur away from the site.
- Describe the border, approximate size, color change across your skin tone, warmth, pain, itching, firmness, swelling, bruising, drainage, red streaks, blistering, darkening, numbness, or breakdown rather than calling everything a “rash.”
- Report fever, chills, feeling acutely unwell, facial or tongue swelling, throat tightness, breathing difficulty, dizziness, fainting, or widespread hives separately from the local skin finding.
- A photo or online symptom list cannot rule out cellulitis, abscess, allergy, bleeding, tissue injury, or another condition when the pattern is concerning.
Route and product identity
Match the reaction to the exact injectable semaglutide product
Semaglutide appears in distinct branded and compounded pathways. Wegovy injection and Ozempic injection have manufacturer labels and product-specific presentations; current official records also include Wegovy tablets and Ozempic tablets, which cannot cause an injection-site reaction. A patient-specific compounded semaglutide injection may use a vial, syringe, different concentration, inactive ingredients, supplies, storage instructions, and pharmacy label. Product identity must be confirmed before label evidence or next-step guidance is applied.
- Record the product name, route, indication, strength or concentration, presentation, package or patient label, refill or lot details, dispensing pharmacy or manufacturer, supplies, shipment, and storage history.
- Tell the clinician whether the skin was already red, swollen, bruised, scarred, hardened, irritated, recently shaved, infected, or affected by eczema or another condition.
- Do not repeat, split, increase, retime, change routes, switch products, or use another injection as a test because a local reaction appeared.
Exposure and history review
Changes around the skin or refill can matter without proving the cause
A reaction review should include everything that touched the area and anything that changed with the prescription. Alcohol preparation, adhesive, bandages, cleansers, lotions, topical medicines, clothing friction, device or needle materials, caregiver assistance, a new refill, a concentration change, shipment conditions, or uncertain storage may be relevant. Timing can suggest questions to investigate, but it does not prove medication allergy, pharmacy error, poor technique, or contamination.
- Share prior injection reactions, medication or adhesive allergies, anaphylaxis or angioedema, eczema or skin disease, diabetes, immune suppression, circulation problems, and bleeding risk.
- List blood thinners, antiplatelet medicines, immune-suppressing medicines, topical products, and any new prescription, over-the-counter medicine, or supplement.
- Preserve a damaged or confusing package and contact the responsible pharmacy or manufacturer rather than using seller chats, forums, copied syringe charts, or improvised device steps.
Compounded-product boundary
Branded trial percentages do not establish a compounded-product rate
Wegovy and Ozempic are FDA-approved finished drug products with manufacturer-controlled labeling. A patient-specific compounded semaglutide preparation is not FDA-approved Wegovy, Ozempic, or an FDA-approved generic finished product. It may differ in concentration, inactive ingredients, presentation, container, supplies, labeling, storage, and beyond-use date. The branded percentages cannot validate a compounded prescription, establish its local-reaction incidence, or explain one patient’s symptoms.
- For compounded semaglutide, verify the patient label, active ingredient, concentration, route, dispensing pharmacy, inactive ingredients when available, supplies, storage, beyond-use date, refill details, and adverse-event contact.
- Ask the pharmacy about a changed label or concentration, particles, cloudiness, discoloration, damage, delayed or warm shipment, uncertain storage, or a different supply before another use decision.
- Avoid research-use vials, counterfeit pens or tablets, unlabeled syringes, copied unit conversions, no-prescription sellers, and claims that a skin reaction proves potency or absorption.
Escalation
Separate routine follow-up from allergy, infection, and tissue emergencies
A mild stable finding and a rapidly worsening reaction require different care paths. Persistent, recurrent, enlarging, worsening, unusually painful, or treatment-limiting symptoms deserve prescriber review even without an emergency feature. Rapidly spreading redness or swelling, increasing warmth or pain, pus, drainage, red streaks, fever, chills, blistering, darkening, numbness, skin breakdown, or feeling acutely unwell can require prompt local assessment. Breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, widespread hives, or a rapidly developing whole-body reaction can require emergency care.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or a rapidly worsening widespread reaction.
- Seek prompt in-person assessment for rapid spread, severe or escalating pain, pus, streaking, fever or chills, blistering, darkening, numbness, or skin breakdown.
- Do not squeeze, puncture, vigorously massage, or use leftover antibiotics, prescription creams, antihistamines, steroids, or home remedies as a substitute for assessment.